AHRQ clinical effectiveness research
This article was originally published in The Gray Sheet
Executive SummaryConsolidated appropriations bill signed into law Dec. 8 provides $15 mil. to Agency for Healthcare Research & Quality for FY 2005 clinical effectiveness research - significantly less than the $50 mil. authorized by the Medicare Modernization Act for the previous fiscal year. The FY 2004 amount was never funded. AdvaMed and Guidant are among stakeholders that submitted comments on AHRQ's research agenda, which initially will focus on pharmaceuticals (1"The Gray Sheet" July 5, 2004, p. 13). Separately, on Dec. 9, AHRQ issued a Federal Register notice inviting nominations of topics for evidence reports and technology assessments. Nominations are due Jan. 31...
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.